Piramal Pharma to buy remaining 26% of Yapan Bio
In short
Piramal Pharma will buy the remaining 26% stake in Yapan Bio. The deal will let Piramal fully bring Yapan’s large-molecule capabilities into its services.
What the reporting says
Piramal Pharma will acquire the remaining 26% stake in Yapan Bio, fully embedding Yapan’s advanced large molecule capabilities into its integrated service offering. The move expands Piramal’s control over the business and strengthens its service platform, according to the source.
Why it matters
Piramal Pharma is acquiring the remaining 26% stake in Yapan Bio, according to the source. The deal is meant to fully embed Yapan’s advanced large molecule capabilities into Piramal’s integrated service offering. That should broaden Piramal’s control over the unit and support its pharma services platform, based on the reported rationale.